Table 1.
Proportion of Overall Pediatric Cancer Discharges | Proportion of Pediatric FN Discharges | |
---|---|---|
% (95% CI) | ||
Patient Characteristics | ||
Gender | ||
Female | 45.0 (44.2–45.8) | 46.5 (45.0–48.0) |
Age | ||
0–4 years | 28.9 (27.8–30.0) | 36.7 (34.6–38.8) |
5–9 years | 22.0 (21.2–22.7) | 27.9 (26.6–29.3) |
10–14 years | 21.3 (20.6–22.0) | 18.2 (17.0–19.6) |
15–19 years | 27.8 (26.6–29.1) | 17.1 (15.7–18.7) |
Race/Ethnicity | ||
White | 48.4 (44.2–52.7) | 55.7 (50.5–60.8) |
Black | 9.7 (8.4–11.2) | 7.1 (5.7–8.7) |
Hispanic | 21.2 (17.7–25.3) | 17.1 (13.6–21.3) |
Asian/Pacific Islander | 7.9 (6.7–9.4) | 7.5 (6.0–9.4) |
Primary Payer | ||
Public | 39.2 (36.7–41.9) | 37.1 (34.2–40.0) |
Private | 53.4 (50.9–55.9) | 57.3 (54.1–60.4) |
Self-pay | 2.2 (1.5–3.1) | 2.4 (1.4–4.0) |
Other | 5.2 (3.9–6.9) | 3.2 (2.5–4.2) |
Mean Household Income per Zip Code | ||
1st quartile | 24.8 (22.5–27.3) | 24.1 (20.7–27.8) |
2nd quartile | 25.3 (50.9–55.9) | 25.1 (23.0–27.2) |
3rd quartile | 25.3 (1.5–3.1) | 24.3 (22.2–26.6) |
4th quartile | 24.6 (21.8–27.6) | 26.5 (22.6–30.8) |
Type of Cancer | ||
ALL | 24.6 (23.5–25.8) | 44.3 (41.6–47.0) |
Bone Cancer | 12.8 (12.0–13.6) | 10.4 (9.1–12.0) |
Central Nervous System Tumor | 9.6 (8.8–10.4) | 6.2 (5.1–7.6) |
AML | 5.9 (5.5–6.3) | 7.4 (5.9–9.1) |
Soft Tissue Sarcoma | 5.1 (4.7–5.6) | 4.6 (3.9–5.4) |
Neuroblastoma | 4.5 (3.9–5.1) | 4.7 (3.7–6.0) |
Hodgkin Lymphoma | 3.2 (2.9–3.5) | 2.9 (2.5–3.4) |
Wilms Tumor | 2.7 (2.5–3.0) | 3.0 (2.5–3.4) |
Non-Hodgkin Lymphoma | 2.6 (2.3–2.9) | 3.6 (3.1–4.3) |
Ovarian or Testicular Tumor | 1.7 (1.5–1.9) | 0.7 (0.5–1.0) |
Hospital Characteristics | ||
Hospital Location-Teaching Status | ||
Rural | 1.7 (1.0–2.8) | 1.6 (0.7–3.3) |
Urban, non-teaching | 9.9 (7.0–13.8) | 7.2 (4.4–11.6) |
Urban, teaching | 88.4 (84.4–91.5) | 91.2 (86.7–94.3) |
Hospital Region | ||
Northeast | 16.3 (11.2–23.0) | 20.7 (13.6–30.2) |
Midwest | 21.5 (15.7–28.8) | 26.0 (18.0–36.0) |
South | 36.3 (28.6–44.8) | 40.2 (29.7–51.8) |
West | 25.9 (18.8–34.4) | 13.1 (7.4–22.2) |